Eyepoint Pharmaceuticals questions Ocular Therapeutix's delayed eye treatment data

statnews.com

Eyepoint Pharmaceuticals CEO publicly questioned Ocular Therapeutix's delayed clinical trial results for a competing eye treatment. The comments, made at an investor conference, suggested Ocular's drug Axpaxli might have negative data, aiming to undermine investor confidence. Both companies are developing treatments for wet age-related macular degeneration, a leading cause of vision loss in the elderly.


With a significance score of 1.5, this news ranks in the top 32% of today's 27729 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Eyepoint Pharmaceuticals questions Ocular Therapeutix's delayed eye treatment data | News Minimalist